Mabpharm Limited (HKG:2181)
Hong Kong · Delayed Price · Currency is HKD 0.3900
-0.0300 (-7.14%)
Sep 18, 2026, 4:08 PM HKT
Mabpharm Market Cap
Mabpharm has a market cap or net worth of 1.61 billion as of September 18, 2026. Its market cap has decreased by -48.68% in one year.
Market Cap
1.61B
Enterprise Value
1.86B
Revenue
888.77M
Ranking
n/a
PE Ratio
19.99
Stock Price
0.39
ChartMarket Cap Chart
Since May 31, 2019, Mabpharm's market cap has decreased from 4.99B to 1.61B, a decrease of -67.77%. That is a compound annual growth rate of -14.35%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 18, 2026 | 1.61B | -22.00% |
| Dec 31, 2025 | 2.06B | 78.57% |
| Dec 31, 2024 | 1.15B | -39.13% |
| Dec 29, 2023 | 1.90B | 5.75% |
| Dec 30, 2022 | 1.79B | -56.50% |
| Dec 31, 2021 | 4.12B | -4.76% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| May 31, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Frontage Holdings | 2.10B |
| AIM Vaccine | 1.98B |
| HighTide Therapeutics | 1.89B |
| Guangzhou Innogen Pharmaceutical Group | 1.76B |
| SinoMab BioScience | 1.56B |
| Shandong Boan Biotechnology | 1.52B |
| Beijing Biostar Pharmaceuticals | 1.49B |
| Zhaoke Ophthalmology | 1.37B |